Acurx Pharmaceuticals Inc (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing antibiotics targeting bacterial infections. It has no approved products and generates no product revenue, funding operations entirely through equity issuances. The company raised net proceeds of approximately $14.8 million from its June 2021 IPO and has continued raising capital through registered direct offerings and private placements since its founding, with early equity financings dating to March 2018. Its lead product candidate is ibezapolstat, and its preclinical pipeline includes ACX-375, a DNA polymerase IIIC (Pol IIIC) inhibitor active against MRSA, MSSA, VRE, and other Gram-positive bacteria. ACX-375 demonstrated oral bioavailability of 31 to 59% across 10 analogs in mouse PK studies and has a novel mechanism of action not impacted by vancomycin, daptomycin, or linezolid resistance. The company outsources substantially all clinical trial activity to contract research organizations and independent investigators. As of the 10-K filed March 12, 2026, Acurx faced a Nasdaq minimum stockholders' equity deficiency notice issued March 25, 2025, which it resolved by August 26, 2025.

Revenue model

No product revenue. Operations funded entirely through equity issuances, including the June 2021 IPO ($14.8 million net proceeds) and subsequent registered direct offerings and private placements. Revenue generation depends on future regulatory approval and commercialization of product candidates.

Products and services

Lead clinical candidate: ibezapolstat (antibiotic). Preclinical candidate: ACX-375, a Pol IIIC inhibitor targeting Gram-positive bacteria including MRSA, MSSA, VRE, and PRSP, with oral and IV formulation development ongoing as of the 10-K filed March 12, 2026.

Customers and end markets

No commercial customers as of the 10-K filed March 12, 2026. Target end market is treatment of Gram-positive bacterial infections, including drug-resistant strains such as MRSA and VRE, in the U.S. prescription drug market, with potential future markets in foreign jurisdictions.

Value-chain role

Drug developer at the clinical and preclinical stage. Outsources manufacturing and clinical trial execution to contract research organizations, independent investigators, and third-party service providers. No internal manufacturing.

Geographic exposure

U.S.-focused clinical development. Foreign jurisdiction regulatory filings and development have not been initiated as of the 10-K filed March 12, 2026.

Source: SEC 10-K, filed 2026-03-12

Industry: Pharmaceutical Preparations Peers: Achieve Life Sciences Inc BioCardia Inc Orgenesis Inc. Lisata Therapeutics Inc CASI Pharmaceuticals, Inc (DE) Cyclerion Therapeutics Inc Eledon Pharmaceuticals Inc Molecular Templates, Inc. Tracon Pharmaceuticals, Inc.